CelebratING 25 Years of the ING Family Proteins as Epigenetic Regulators in Cancer
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 5921
Special Issue Editors
Interests: Function of Tumour Suppressors and Epigenetic Regulators in Cancer and Ageing
Department of Paediatrics, Hematology-Oncology-Transplant (HOT)-Program, Alberta Children’s Hospital, 28 Oki Drive N.W., Calgary, Alberta T3B 6A8, Canada
Interests: Pediatric (Neuro-)Oncology; Long-Term Sequelae in Childhood Cancer Survivors
Special Issue Information
Dear Colleagues,
We would like to introduce a Special Issue of the journal Cancers, titled "CelebratING 25 years of the ING family proteins as epigenetic regulators in cancer".
Cancer cells accumulate genetic and epigenetic changes that alter gene expression to drive tumorigenesis. The epigenetic silencing of tumor suppressor, cell cycle, differentiation and DNA repair genes contributes to neoplastic transformation.
The founding member of the ING (inhibitor of growth) family, ING1, was discovered in 1996 by PCR-mediated subtractive hybridization using cDNAs from a normal mammary epithelial cell strain and several transformed breast cancer cell lines, followed by an in vivo functional screen to identify differentially expressed factors impacting tumorigenesis. Back then, the overexpression of ectopic ING1 was observed to promote cell cycle arrest or apoptosis, while the inhibition of its expression with antisense RNA led to cellular transformation in vitro and tumor formation in vivo. Subsequently, four more ING proteins (ING2–ING5) were identified in mammals based on sequence homology to ING1.
Over the past 25 years, ING1–ING5 have been described as a multifaceted family of growth and senescence regulators, DNA repair modulators, phospholipid effectors, histone mark sensors and core components of HDAC1/2, several HAT chromatin-modifying complexes and governors of stem cell differentiation.
This Special Issue will provide the most current insights into ING structure, the pathways by which ING family proteins differentially affect the Hallmarks of Cancer and highlight the various epigenetic mechanisms by which they regulate gene expression and may serve as biomarkers and therapeutic targets in future epigenetic treatment strategies for cancer patients.
Prof. Dr. Karl Riabowol
Prof. Dr. Gesche Tallen
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ING Proteins
- Epigenetic Readers
- Histone Acetylation
- Tumour Suppressors
- Stem Cells
- PHD
- Chromatin
- DNA Repair
